Martin Auster
Stock Analyst at Raymond James
(2.69)
# 2,165
Out of 5,111 analysts
56
Total ratings
59.52%
Success rate
14.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $74.51 | -4.71% | 2 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | n/a | $71.86 | - | 2 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $92.00 | +17.39% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $213.24 | +27.09% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $19.59 | +78.66% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $391.50 | +8.30% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $52.12 | +130.24% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $36.23 | +189.82% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $12.92 | +101.24% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $5.71 | +2,001.58% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $725 → $300 | $31.60 | +849.37% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $32.98 | +75.86% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $500.30 | -60.82% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.40 | +6,900.00% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $196.92 | -69.53% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $45.24 | +43.68% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $21.55 | +238.75% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.00 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $20.43 | +281.79% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.78 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $10.56 | +307.20% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $9.14 | +129.76% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $45.56 | -64.88% | 1 | May 7, 2020 |
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $74.51
Upside: -4.71%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $71.86
Upside: -
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $92.00
Upside: +17.39%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $213.24
Upside: +27.09%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $19.59
Upside: +78.66%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $391.50
Upside: +8.30%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $52.12
Upside: +130.24%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $36.23
Upside: +189.82%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $12.92
Upside: +101.24%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.71
Upside: +2,001.58%
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $31.60
Upside: +849.37%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $32.98
Upside: +75.86%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $500.30
Upside: -60.82%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.40
Upside: +6,900.00%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $196.92
Upside: -69.53%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $45.24
Upside: +43.68%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $21.55
Upside: +238.75%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.00
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $20.43
Upside: +281.79%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.78
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $10.56
Upside: +307.20%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $9.14
Upside: +129.76%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $45.56
Upside: -64.88%